Research
Hormonal
Patients treated with semaglutide 2.4 mg had lower rates of all-cause death compared to placebo (HR: 0.81; 95% CI: 0.71-0.93).
Semaglutide may be an effective treatment for reducing overall mortality in patients with cardiovascular disease.
StrongSupportsmedium confidence
Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93).
Why this rating
Based on a large randomized controlled trial.
Source
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Benjamin M. Scirica et al. · Journal of the American College of Cardiology · 2024
rct · n=833Cited 43×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →